RE:Churning thru financings shares
I could be waaaaay off base here but the near term catalyst of a BLA submission as well as the "value drivers" noted in the corporate presentation should be driving demand that would nullify any profit taking from the two financings that you speak of. It is not. If fact there is very little demand for shares above 30 cents. Why is the company valued at 1/5th or less than that of its peers?Is that a product of the IR and PR executive effort or a reflection on the confidence in the success of the submission? I think that it is the former. It is difficult to be confident in and invest in something that you are vaguely aware of.Oh I don't think that posters here can continue renting the mule of old management for the purposes of explaining the valuation. It has been 7 months since the market was told that the FDA is allowing a March 2015 BLA submission.